San Marcos, CA, United States of America

Alan D Agulnick

This inventor holds 39 USPTO granted patents and 21 published patent applications, plus 10 CIPO patents and 14 EPO patents, primarily in Stem Cell Research. Top assignees: Viacyte, Inc., Cythera, Inc., University of Georgia Research Foundation Inc. Active years: 2009-2026.

USPTO Granted Patents = 39 (Patent Applications = 21)

% Patents Active = 94.9

CIPO Patents = 10 (Patent Applications = 4)

EPO Patents = 14 (Patent Applications = 9)

Average Co-Inventor Count = 3.3

ph-index = 19

Forward Citations = 1,543(Granted Patents)

Location History:

San Marcos, CA (US) (2009 - 2012)
San Digeo, CA (US) (2018)
San Diego, CA (US) (2010 - 2024)

Company Filing History:

University of Georgia Research Foundation Inc

patents

where one patent can have more than one assignee

Years Active: 2009-2026

Loading Chart...

Areas of Expertise:

Universal Donor Cells

Pancreatic Progenitor Cells

Definitive Endoderm

Cryopreservation

Pluripotent Stem Cells

In Vitro Differentiation

Hormone Secreting Cells

Endocrine Cells

Cell Compositions

Reprogrammed Cells

Stem Cell Aggregate

Factors for Differentiation

39 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12576142 - UNIVERSAL DONOR CELLS AND RELATED METHODS (2026-03-17),

2. 11905530 - Cell encapsulation device comprising a pancreatic progenitor cell population (2024-02-20),

3. 11904001 - Universal donor cells and related methods (2024-02-20),

4. 11746323 - PDX1 positive foregut endoderm cells and methods of production (2023-09-05),

5. 11667889 - Methods of making human primitive ectoderm cells (2023-06-06),

6. 11446335 - Cryopreserved endocrine cells that express chromogranin A (2022-09-20),

7. 11427805 - Methods of producing human foregut endoderm cells expressing PDX1 from human definitive endoderm (2022-08-30),

8. 10695380 - Cryopreservation of encapsulated pancreatic endoderm cells (2020-06-30),

9. 10550367 - Methods of making human primitive ectoderm cells (2020-02-04),

10. 10465162 - Anterior endoderm cells and methods of production (2019-11-05),

11. 10421942 - Definitive endoderm (2019-09-24),

12. 10391156 - University donor cells and related methods (2019-08-27),

13. 10376545 - Methods for producing hormone secreting cells in a subject (2019-08-13),

14. 10179902 - Methods of making human primitive ectoderm cells (2019-01-15),

15. 9988604 - Cell compositions derived from dedifferentiated reprogrammed cells (2018-06-05),

Title: Alan D. Agulnick: Pioneering Innovations in Stem Cell Technology

Introduction

Alan D. Agulnick, based in San Marcos, CA, is a distinguished inventor with an impressive portfolio of 38 patents. His innovative contributions primarily focus on advancements in stem cell technology and cell-based therapies, making significant impacts in the medical field.

Latest Patents

Among his latest patents are two notable inventions. The first is a "Cell encapsulation device comprising a pancreatic progenitor cell population," which includes cell culture compositions derived from dedifferentiated human reprogrammed pluripotent stem cells, such as induced pluripotent stem (iPS) cells. This invention details methods for producing and utilizing these specific cell culture compositions.

The second patent, "Universal donor cells and related methods," introduces universal donor stem cells, which are crucial for overcoming allogeneic immune rejection in cell-based transplantation therapies. These universal donor cells are designed such that they do not express certain MHC-Class I cell-surface proteins, thereby enhancing their compatibility for transplantation purposes.

Career Highlights

Throughout his career, Alan has worked with leading biotech companies including Viacyte, Inc. and Cythera, Inc. His work has been pivotal in the development of therapies that leverage stem cells for regenerative medicine, marking him as a prominent figure in the industry.

Collaborations

Alan D. Agulnick has collaborated with notable professionals such as Kevin Allen D'Amour and Emmanuel Edward Baetge. These collaborations have further expanded the scope of his innovation, blending expertise to address complex challenges in stem cell research and therapeutic applications.

Conclusion

With a robust portfolio of patents and valuable contributions to the field of stem cell technology, Alan D. Agulnick exemplifies the spirit of innovation. His dedication to enhancing medical therapies through scientific advancements continues to influence the future of regenerative medicine and transplantation.